FDA Approves Drug For Most Common Skin Cancer
CBS DFW (con't)
Affordable Care Act Updates: CBSDFW.com/ACA
Health News & Information: CBSDFW.com/Health
Get Breaking News First
NEW YORK (CBS) - The FDA has approved a new drug called Erivedge to treat basal cell carcinoma, the most common form of skin cancer. Federal regulators announced Monday the approval of the Erivedge pill, the first drug ever approved for treating basal cell carcinoma. Typical BCC treatments include outpatient procedures such as freezing or surgically removing the cancerous area. The pill is made by Genentech, a unit of Swiss drugmaker Roche. Erivedge is a once-per-day capsule that’s intended to treat locally advanced cancer for patients who are not candidates for surgery or radiation, and for patients whose cancer has spread to other parts of the body.
Also Check Out: